Light Activated Therapies

Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies - Distribution by Target Indications (Head and Neck Cancer, Actinic Keratosis, Macular Degeneration, Polypoidal Choroidal Vasculopathy, Cervical Intraepithelial Neoplasia, Bladder Cancer, Barrett’s Esophagus, Gastric Cancer, Lung Cancer, Port-Wine Stain and Others), Key Players and Geographies (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2021

  • Pages
    140

  • View Count
    3486

  • Buy Now

Example Insights

Light-Activated-Therapies-Market-Context Light-Activated-Therapies-Market-List Light-Activated-Therapies-Market-Distribution
Light-Activated-Therapies-Market-Development-Pipeline Light-Activated-Therapies-Market-Clinical-Trial-Analysis Light-Activated-Therapies-Market-Patent-Analysis
Light-Activated-Therapies-Market-Distribution-of-Key-Player    

Overview

According to the World Health Organization, in a year, around 2 million to 3 million individuals suffer from various forms of skin cancers, across the globe. This type of cancer account for 33% of all the diagnosed tumors, globally. It is also worth highlighting that one in every five Americans is likely to develop some form of skin cancer in their lifetime. Although efforts are being made to develop safe and effective drugs for the treatment of different types of skin cancer, there is still a pressing need for more specific and potent drugs / therapies to combat this complex clinical condition. Amidst the current initiatives to develop more targeted anti-cancer therapies, light activated therapies (specifically photodynamic therapies, photoimmunotherapies and photothermal therapies) have emerged as a promising alternative, owing to their capability to eradicate diseased cells from the body with minimal side effects. Unlike chemotherapy or radiotherapy, light activated therapies only destroy cancerous cells without damaging the surrounding healthy tissues. Therefore, this novel therapeutic approach has various advantages over conventional treatments for cancer and various skin diseases, such as acne, actinic keratosis, microvesicles, warts and others.

Over time, several pharmaceutical companies have undertaken various initiatives to develop effective photodynamic therapies / photoimmunotherapies against multiple target indications. At present, the pipeline features close to 130 candidates, and this value is anticipated to grow further in the foreseen future. Of these, more than 10 therapies, including ASP-1929 (Rakuten Medical), VISUDYNE® (Novartis), Metvix® (Galderma), PHOTOFRIN® (ADVANZ PHARMA), Ameluz® (Biofrontera) and LEVULAN® KERASTICK™ (Sun Pharma), have already been marketed. Further, over 635 patents related to light activated therapies have been filed / granted in the past three years, demonstrating the continued innovation in this domain. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials of such therapy candidates. With multiple therapeutic leads in the mid to late stages of development (phase II and above), we are led to believe that the light activated therapies market is likely to witness significant growth in the foreseen future.

Scope of the Report

The “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies, 2021-2030 - Distribution by Target Indications (Head and Neck Cancer, Actinic Keratosis, Macular Degeneration, Polypoidal Choroidal Vasculopathy, Cervical Intraepithelial Neoplasia, Bladder Cancer, Barrett’s Esophagus, Gastric Cancer, Lung Cancer, Port-Wine Stain and Others), Key Players and Key Geographies (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts” report features an extensive study of the current market landscape and the likely adoption of light activated therapies, over the next decade.  The study features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of light activated therapies, with respect to current status of development (preclinical / discovery, phase I, phase I / II, phase II, phase II / III, phase III and approved), type of light activated therapy (photodynamic therapy, photoimmunotherapy and photothermal therapy), therapeutic area (oncological disorders (solid tumor), dental disorders, skin disorders,  oncological disorders (hematological cancer) and others), type of photosensitive dye (methylene blue, phthalocyanine dye, indocyanine green, toluidine blue and phenothiazine hydrochloride), type of light (red light, blue light, infrared light, near-infrared light, visible light, ultraviolet light and daylight), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy), type of developer (industry / non-industry) and popular target indications (periodontitis, actinic keratosis, basal cell carcinoma, head and neck cancer, lung cancer, cholangiocarcinoma, dental caries, squamous cell carcinoma, acne, bladder cancer, COVID-19, pancreatic cancer, prostate cancer and others). In addition, the chapter includes analysis on the light activated therapy developer(s) based on various relevant parameters, including year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
  • Detailed profiles of marketed and late stage (phase III) clinical products; each profile features an overview of the company, therapy overview, clinical development status, clinical trial endpoints, dosage information, key insights, clinical trial endpoints and estimated sales revenue (2021-2030). 
  • An in-depth analysis of completed, ongoing and planned clinical studies of various light activated therapies based on relevant parameters, such as trial registration year, study design and trial phase, type of masking and type of intervention model, year and trial recruitment status, type of sponsor, most active industry and non-industry players (in terms of number of registered trials conducted), purpose of study, emerging focus area, location of trial, and key geographical regions.
  • An analysis of patents filed / granted related to light activated therapies, till 2021. The instances have been analyzed based on various relevant parameters, such as publication year, type of patent, patent age, geographical location, CPC symbols, emerging focus areas, leading patent assignees, leading industry and non-industry players (in terms of number of patents filed / granted), patent benchmarking and valuation.  
  • Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) including brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for light activated therapies over the coming decade. Additionally, it features market size projections for the overall light activated therapies market, wherein both the current and upcoming opportunity is segmented across [A] target indications (head and neck cancer, actinic keratosis, macular degeneration, polypoidal choroidal vasculopathy, cervical intraepithelial neoplasia, bladder cancer, Barrett’s esophagus, gastric cancer, lung cancer, port-wine stain and others), [B] key players and [C] key geographies (North America, Europe, Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

Key Questions Answered

  • What are the prevalent R&D trends related to light activated therapies?
  • What are the key therapeutic areas for which light activated therapies are being / have been developed?
  • What are the key challenges faced by stakeholders related to manufacturing of light activated therapies?
  • Who are the leading industry and non-industry players engaged in the development of light activated therapies?
  • Across which geographies, extensive research related to light activated therapies is being conducted?
  • Which factors are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments? 

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the light activated therapies market in the short to mid-term and long term.

Chapter 3 provides a general overview of light activated therapies. In this section, we have briefly discussed the advantages and general mechanism of action of various type of light activated therapies, including photoimmunotherapies, photodynamic therapies and photothermal therapies. 

Chapter 4 includes detailed assessment on more than 125 light activated therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the current status of development (preclinical / discovery, phase I, phase I / II, phase II, phase II / III, phase III and approved), type of light activated therapy (photodynamic therapy, photoimmunotherapy and photothermal therapy), therapeutic area (oncological disorders (solid tumor), dental disorders, skin disorders,  oncological disorders (hematological cancer) and others), type of photosensitive dye (methylene blue, phthalocyanine dye, indocyanine green, toluidine blue and phenothiazine hydrochloride), type of light (red light, blue light, infrared light, near-infrared light, visible light, ultraviolet light and daylight), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy), type of developer (industry / non-industry) and popular target indications (periodontitis, actinic keratosis, basal cell carcinoma, head and neck cancer, lung cancer, cholangiocarcinoma, dental caries, squamous cell carcinoma, acne, bladder cancer, COVID-19, pancreatic cancer, prostate cancer and others). In addition, the chapter includes information on the light activated therapy developer(s), highlighting their year of establishment, company size, and location of headquarters and most active players (in terms of number of pipeline candidates).

Chapter 5 provides detailed profiles of marketed and late-stage clinical products (phase III). Each profile features an overview of the therapy, clinical development status, clinical trial endpoints, dosage information, key clinical trial results and estimated sales revenue (2021-2030). 

Chapter 6 presents an in-depth analysis of completed, ongoing and planned clinical studies of various light activated therapies based on relevant parameters, such as trial registration year, study design and trial phase, type of masking and type of intervention model, year and trial recruitment status, type of sponsor, most active industry and non-industry players (in terms of number of registered trials conducted), purpose of study, emerging focus area, location of trial, and key geographical regions

Chapter 7 provides analysis on over 635 patents filed / granted related to light activated therapies, till 2021. The instances have been analyzed based on various relevant parameters, such as publication year, type of patent, patent age, geographical location, CPC symbols, emerging focus areas, leading patent assignees, leading industry and non-industry players (in terms of number of patents filed / granted), patent benchmarking and valuation.  

Chapter 8 presents an insightful market forecast analysis, highlighting the future potential of light activated therapies till the year 2030. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] target indications (head and neck cancer, actinic keratosis, macular degeneration, polypoidal choroidal vasculopathy, cervical intraepithelial neoplasia, bladder cancer, Barrett’s esophagus, gastric cancer, lung cancer, port-wine stain and others), [B] key players and [C] key geographies (North America, Europe, Asia Pacific and rest of the world).

Chapter 9 includes brief overview of the company (including information on their year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details on their respective product portfolio, recent developments and an informed future outlook.

Chapter 10 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 12 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Light Activated Therapies 
3.2. Types of Light Activated Therapies 
3.3. Components of Light Activated Therapies
3.3.1. Photosensitizing Substance 
3.3.2. Light Source and Device
3.4. Advantages of Light Activated Therapies

3.5. Photoimmunotherapy
3.5.1 Mechanism of Action of Photoimmunotherapies
3.6. Photodynamic Therapy
3.6.1. Mechanism of Action of Photodynamic Therapy
3.6.2. Advantages and Challenges Associated with Photodynamic Therapy
3.7. Photothermal Therapy 
3.7.1. Mechanism of Action of Photothermal Therapy

3.8. Difference between Photodynamic and Photothermal Therapy

4. MARKET LANDSCAPE
4.1. Light Activated Therapies: Overall Market Landscape
4.1.1. Analysis by Current Status of Development
4.1.2. Analysis by Type of Light Activated Therapy
4.1.3. Analysis by Therapeutic Area
4.1.4. Analysis by Current Status of Development and Therapeutic Area
4.1.5. Analysis by Type of Photosensitive Dye
4.1.6. Analysis by Type of Light
4.1.7. Analysis by Target Patient Segment
4.1.8. Analysis by Type of Therapy
4.1.9. Analysis by Type of Developer
4.1.10. Analysis by Popular Target Indications
4.1.11. Leading Industry Players: Analysis by Number of Light Activated Therapies
4.1.12. Leading Non-Industry Players: Analysis by Number of Light Activated Therapies

4.2. Light Activated Therapies: List of Developers
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Regional Landscape of Developers

5. THERAPY PROFILES
5.1. Chapter Overview
5.2. Cetuximab Sarotalocan®
5.2.1. Company Overview
5.2.2. Therapy Overview
5.2.3. Clinical Development Status
5.2.4. Clinical Trial Endpoints
5.2.5. Dosage Regimen
5.2.6. Key Insights
5.2.7. Estimated Sales Revenue

5.3. Photodynamic Therapy and Alacare®
5.3.1. Company Overview
5.3.2. Therapy Overview
5.3.3. Clinical Development Status
5.3.4. Clinical Trial Endpoints
5.3.5. Dosage Regimen
5.3.6. Key Insights
5.3.7. Estimated Sales Revenue

5.4. Photodynamic Therapy and Ameluz®
5.4.1. Company Overview
5.4.2. Therapy Overview
5.4.3. Clinical Development Status
5.4.4. Dosage Regimen
5.4.5. Key Insights
5.4.6. Estimated Sales Revenue

5.5. Photodynamic Therapy and Aminolevulinic Acid
5.5.1. Company Overview
5.5.2. Therapy Overview
5.5.3. Clinical Development Status
5.5.4. Key Insights
5.5.5. Estimated Sales Revenue

5.6. Photodynamic Therapy and Foscan® (Temoporfin)
5.6.1. Company Overview
5.6.2. Therapy Overview
5.6.3. Clinical Development Status
5.6.4. Clinical Trial Endpoints
5.6.5. Dosage Regimen
5.6.6. Key Insights
5.6.7. Estimated Sales Revenue

5.7. Photodynamic Therapy and FuMeiDa® (Hemoporfin)
5.7.1. Company Overview
5.7.2. Therapy Overview
5.7.3. Clinical Development Status
5.7.4. Clinical Trial Endpoints
5.7.5. Dosage Regimen
5.7.6. Key Insights
5.7.7. Estimated Sales Revenue

5.8. Photodynamic Therapy and Levulan Kerastick®
5.8.1. Company Overview
5.8.2. Therapy Overview
5.8.3. Clinical Development Status
5.8.4. Dosage Regimen
5.8.5. Key Insights
5.8.6. Estimated Sales Revenue

5.9. Photodynamic Therapy and Metvixia® (Metvix)
5.9.1. Company Overview
5.9.2. Therapy Overview
5.9.3. Clinical Development Status
5.9.4. Clinical Trial Endpoints
5.9.5. Dosage Regimen
5.9.6. Key Insights
5.9.7. Estimated Sales Revenue

5.10. Photodynamic Therapy and Porfimer Sodium / Photofrin®
5.10.1. Company Overview
5.10.2. Therapy Overview
5.10.3. Clinical Development Status
5.10.4. Clinical Trial Endpoints
5.10.5. Dosage Regimen
5.10.6. Estimated Sales Revenue

5.11. Photodynamic Therapy and Verteporfin® (Visudyne)
5.11.1. Company Overview
5.11.2. Therapy Overview
5.11.3. Clinical Development Status
5.11.4. Clinical Trial Endpoints
5.11.5. Dosage Regimen
5.11.6. Key Insights
5.11.7. Estimated Sales Revenue

5.12. TOOKAD® VTP
5.12.1. Company Overview
5.12.2. Therapy Overview
5.12.3. Clinical Development Status
5.12.4. Clinical Trial Endpoints
5.12.5. Dosage Regimen
5.12.6. Key Insights
5.12.7. Estimated Sales Revenue

6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters 
6.2. Light Activated Therapies: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Study Design and Trial Phase
6.3.3. Analysis by Type of Masking and Intervention Model
6.3.4. Analysis by Year and Trial Recruitment Status
6.3.5. Analysis by Type of Sponsor
6.3.6. Leading Industry Players: Analysis by Number of Trials Registered
6.3.7. Leading Non-Industry Players: Analysis by Number of Trials Registered
6.3.8. Analysis by Purpose of Study
6.3.9. Analysis by Trial Recruitment Status
6.3.10. Analysis by Emerging Focus Area
6.3.11. Analysis by Location of Trial
6.3.12. Analysis by Trial Status and Geography

7. PATENT ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Light Activated Therapies: Patent Analysis
7.2.1. Analysis by Publication Year
7.2.2. Analysis by Type of Patent
7.2.3. Analysis by Patent Age
7.2.4. Analysis by Geographical Location
7.2.5. Analysis by Emerging Focus Areas 
7.2.6. Leading Patent Assignees: Analysis by Number of Patents
7.2.7. Analysis by Type of Players
7.2.8. Leading Industry Players: Analysis by Number of Patents
7.2.9. Leading Non-Industry Players: Analysis by Number of Patents
7.2.10. Analysis by CPC Symbols
7.2.11. Light Activated Therapies: Patent Benchmarking Analysis
7.2.12. Light Activated Therapies: Patent Valuation Analysis

8. MARKET SIZING AND OPPORTUNITY ANALYSIS
8.1. Forecast Methodology and Key Assumptions
8.2. Overall Light Activated Therapies Market, 2021-2030
8.2.1. Light Activated Therapies Market: Analysis by Target Indication
8.2.2. Light Activated Therapies Market: Analysis by Key Players
8.2.3. Light Activated Therapies Market: Analysis by Geography
8.2.4. Light Activated Therapies: Forecast of Individual Product Sales 

8.2.4.1. Cetuximab Sarotalocan® (Rakuten Medical): Estimated Sales Revenues
8.2.4.2. Photodynamic Therapy and Alacare® (medec): Estimated Sales Revenues
8.2.4.3. Photodynamic Therapy and Ameluz® (Biofrontera): Estimated SalesRevenues
8.2.4.4. Photodynamic Therapy and Aminolevulinic Acid (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Estimated Sales Revenues
8.2.4.5. Photodynamic Therapy and Foscan® (biolitec Pharma): Estimated SalesRevenues
8.2.4.6. Photodynamic Therapy and FuMeiDa® (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Estimated Sales Revenues
8.2.4.7. Photodynamic Therapy and Levulan Kerastick® (Sun Pharmaceuticals):Estimated Sales Revenues
8.2.4.8. Photodynamic Therapy and Metvixia® / Metvix® (Galderma): Estimated SalesRevenues
8.2.4.9. Photodynamic Therapy and Porfimer Sodium / Photofrin® (ADVANZPHARMA): Estimated Sales Revenues
8.2.4.10. Photodynamic Therapy and Verteporfin® / Visudyne® (Novartis): EstimatedSales Revenues
8.2.4.11. Photodynamic Therapy and TLD-1433 (Theralase): Estimated Sales Revenues
8.2.4.12. TOOKAD® VTP (Steba biotech): Estimated Sales Revenues

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. ADVANZ PHARMA
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Product Portfolio

9.3. Biofrontera
9.3.1. Company Overview
9.3.2. Financial Information
9.3.3. Key Insights
9.3.4. Product Portfolio
9.3.5. Recent Developments and Future Outlook

9.4. biolitec Pharma
9.4.1. Company Overview
9.4.3. Product Portfolio

9.5. Luzitin
9.5.1. Company Overview
9.5.2. Product Portfolio
9.5.3. Recent Developments and Future Outlook

9.6. Nanospectra Biosciences
9.6.1. Company Overview
9.6.2. Product Portfolio
9.6.3. Key Insights
9.6.4. Recent Developments and Future Outlook

9.7. photoatomic
9.7.1. Company Overview
9.7.2. Product Portfolio
9.7.3. Key Insights
9.7.4. Recent Developments and Future Outlook

9.8. Rakuten Medical
9.8.1. Company Overview
9.8.2. Financial Information
9.8.3. Product Portfolio
9.8.4. Key Insights
9.8.5. Recent Developments and Future Outlook

9.9. Steba biotech
9.9.1. Company Overview
9.9.2. Product Portfolio
9.9.3. Key Insights
9.9.4. Recent Developments and Future Outlook

9.10. Theralase
9.10.1. Company Overview
9.10.2. Financial Information
9.10.3. Product Portfolio
9.10.4. Key Insights
9.10.5. Recent Developments and Future Outlook

10. CONCLUSION

11. APPENDIX 1: TABULATED DATA

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Patent Analysis
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Types of Light Activated Therapies
Figure 3.2 Mechanism of Action of Photoimmunotherapies
Figure 3.3 Mechanism of Action of Photodynamic Therapy
Figure 3.4 Advantages and Challenges associated with Photodynamic Therapy
Figure 3.5 Mechanism of Action of Photothermal Therapy
Figure 4.1 Light Activated Therapies: Distribution by Current Status of Development
Figure 4.2 Light Activated Therapies: Distribution by Type of Light Activated Therapy
Figure 4.3 Light Activated Therapies: Distribution by Therapeutic Area
Figure 4.4 Light Activated Therapies: Distribution by Current Status of Development andTherapeutic Area
Figure 4.5 Light Activated Therapies: Distribution by Photosensitive Dye
Figure 4.6 Light Activated Therapies: Distribution by Type of Light
Figure 4.7 Light Activated Therapies: Distribution by Target Patient Segment
Figure 4.8 Light Activated Therapies: Distribution by Type of Therapy
Figure 4.9 Light Activated Therapies: Distribution by Type of Developer
Figure 4.10 Light Activated Therapies: Distribution by Popular Target Indications
Figure 4.11 Leading Industry Players: Distribution by Number of Light Activated Therapies
Figure 4.12 Leading Non-Industry Players: Distribution by Number of Light Activated Therapies
Figure 4.13 Light Activated Therapy Developers: Distribution by Year of Establishment
Figure 4.14 Light Activated Therapy Developers: Distribution by Company Size
Figure 4.15 Light Activated Therapy Developers: Distribution by Location of Headquarters
Figure 4.16 Light Activated Therapy Developers: Regional Landscape
Figure 5.1 Cetuximab Sarotalocan®: Estimated sales revenue
Figure 5.2 Photodynamic Therapy and Alacare®: Estimated sales revenue
Figure 5.3 Photodynamic Therapy and Ameluz®: Estimated sales revenue
Figure 5.4 Photodynamic Therapy and Aminolevulinic Acid: Estimated salesrevenue
Figure 5.5 Photodynamic Therapy and Foscan® (Temoporfin): Estimated salesrevenue
Figure 5.6 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Estimated salesrevenue
Figure 5.7 Photodynamic Therapy and Levulan Kerastick®: Estimated sales
Figure 5.8 Photodynamic Therapy and Metvixia® (Metvix): Estimated sales
Figure 5.9 Photodynamic Therapy and Porfimer Sodium / Photofrin®: Estimatedsales revenue
Figure 5.10 Photodynamic Therapy and Verteporfin® (Visudyne): Estimated salesrevenue 
Figure 5.12 Photodynamic Therapy and TOOKAD® VTP: Estimated sales revenue
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 6.2 Clinical Trial Analysis: Distribution by Study Design and Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model
Figure 6.4 Clinical Trial Analysis: Distribution by Year and Trial Recruitment Status
Figure 6.5 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 6.6 Leading Industry Players: Distribution by Number of Trials Registered
Figure 6.7 Leading Non-Industry Players: Distribution by Number of Trials Registered
Figure 6.8 Clinical Trial Analysis: Distribution by Purpose of Study
Figure 6.9 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.10 Clinical Trial Analysis: Distribution by Emerging Focus Area
Figure 6.11 Clinical Trial Analysis: Distribution by Location of Trial(s)
Figure 6.12 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 7.1 Patent Analysis: Distribution by Publication Year
Figure 7.2 Patent Analysis: Distribution by Type of Patent
Figure 7.3 Patent Analysis: Distribution by Patent Age
Figure 7.4 Patent Analysis: Distribution by Geographical Location
Figure 7.5 Patent Analysis: Distribution by Emerging Focus Areas
Figure 7.6 Leading Patent Assignees: Distribution by Number of Patents
Figure 7.7 Leading Industry Players: Distribution by Number of Patents
Figure 7.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.9 Patent Analysis: Distribution by CPC Symbols
Figure 7.10 Light Activated Therapies: Patent Benchmarking
Figure 7.11 Light Activated Therapies: Patent Valuation
Figure 8.1 Light Activated Therapies Market, 2021-2030 (USD Million)
Figure 8.2 Light Activated Therapies Market, 2021-2030: Distribution by Target Indication (USD Million)
Figure 8.3 Light Activated Therapies Market, 2021-2030: Distribution by Key Players (USD Million)
Figure 8.4 Light Activated Therapies Market, 2021-2030: Distribution by Geography (USD Million)
Figure 8.5 Cetuximab Sarotalocan® (Rakuten Medical): Sales Forecast, 2021-2030 (USD Million)
Figure 8.6 Photodynamic Therapy and Alacare® (medec): Sales Forecast, 2021-2030(USD Million)
Figure 8.7 Photodynamic Therapy and Ameluz® (Biofrontera): Sales Forecast, 2021-2030(USD Million)
Figure 8.8 Photodynamic Therapy and Aminolevulinic Acid (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030 
Figure 8.9 Photodynamic Therapy and Foscan® (Temoporfin) (biolitec Pharma): SalesForecast, 2021-2030 (USD Million)
Figure 8.10 Photodynamic Therapy and FuMeiDa® (Hemoporfin) (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030 (USD Million)
Figure 8.11 Photodynamic Therapy and Levulan Kerastick® (Sun Pharmaceuticals): SalesForecast, 2021-2030 (USD Million)
Figure 8.12 Photodynamic Therapy and Metvixia® (Metvix) (Galderma): Sales Forecast,2021-2030 (USD Million)
Figure 8.13 Photodynamic Therapy and Porfimer Sodium / Photofrin® (ADVANZPHARMA): Sales Forecast, 2021-2030 (USD Million)
Figure 8.14 Photodynamic Therapy and Verteporfin® (Visudyne) (Novartis): SalesForecast, 2021-2030 (USD Million)
Figure 8.15 Photodynamic Therapy and TLD-1433 (Theralase): Sales Forecast, 2021-2030(USD Million)
Figure 8.16 Photodynamic Therapy and TOOKAD® VTP (Steba biotech): Sales Forecast,2021-2030 (USD Million)
Figure 9.1 ADVANZ PHARMA: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 9.2 Biofrontera: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 9.6 Rakuten Medical: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 9.7 Theralase: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 10.1 Concluding Remarks: Overall Market Landscape
Figure 10.2 Concluding Remarks: Clinical Trial Analysis
Figure 10.3 Concluding Remarks: Patent Analysis
Figure 10.4 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 Light Activated Therapies: Drug Pipeline
Table 4.2 Light Activated Therapies: List of Developers
Table 5.1 Cetuximab Sarotalocan®: Clinical Developmental Status
Table 5.2 Cetuximab Sarotalocan®: Clinical Trial Endpoints
Table 5.3 Cetuximab Sarotalocan®: Dosage Regimen
Table 5.4 Cetuximab Sarotalocan®: Key Insights
Table 5.5 Photodynamic Therapy and Alacare®: Clinical Developmental Status
Table 5.6 Photodynamic Therapy and Alacare®: Clinical Trial Endpoints
Table 5.7 Photodynamic Therapy and Alacare®: Dosage Regimen
Table 5.8 Photodynamic Therapy and Alacare®: Key Insights
Table 5.9 Photodynamic Therapy and Ameluz®: Clinical Developmental Status
Table 5.10 Photodynamic Therapy and Ameluz®: Clinical Trial Endpoints
Table 5.11 Photodynamic Therapy and Ameluz®: Dosage Regimen
Table 5.12 Photodynamic Therapy and Ameluz®: Key Insights
Table 5.13 Photodynamic Therapy and Aminolevulinic Acid: Clinical DevelopmentalStatus
Table 5.14 Photodynamic Therapy and Aminolevulinic Acid: Key Insights
Table 5.15 Photodynamic Therapy and Foscan® (Temoporfin): Clinical DevelopmentalStatus
Table 5.16 Photodynamic Therapy and Foscan® (Temoporfin): Clinical Trial Endpoints
Table 5.17 Photodynamic Therapy and Foscan® (Temoporfin): Dosage Regimen
Table 5.18 Photodynamic Therapy and Foscan® (Temoporfin): Key Insights
Table 5.19 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Clinical DevelopmentalStatus
Table 5.20 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Clinical Trial Endpoints
Table 5.21 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Dosage Regimen
Table 5.22 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Key Insights
Table 5.23 Photodynamic Therapy and Levulan Kerastick®: Clinical DevelopmentalStatus
Table 5.24 Photodynamic Therapy and Levulan Kerastick®: Clinical Trial Endpoints
Table 5.25 Photodynamic Therapy and Levulan Kerastick®: Dosage Regimen
Table 5.26 Photodynamic Therapy and Levulan Kerastick®: Key Insights
Table 5.27 Photodynamic Therapy and Metvixia® (Metvix): Clinical DevelopmentalStatus
Table 5.28 Photodynamic Therapy and Metvixia® (Metvix): Clinical Trial Endpoints
Table 5.29 Photodynamic Therapy and Metvixia® (Metvix): Dosage Regimen
Table 5.30 Photodynamic Therapy and Metvixia® (Metvix): Key Insights
Table 5.31 Photodynamic Therapy and Porfimer Sodium / Photofrin®: ClinicalDevelopmental Status
Table 5.32 Photodynamic Therapy and Porfimer Sodium / Photofrin®: Clinical Trial Endpoints
Table 5.33 Photodynamic Therapy and Porfimer Sodium / Photofrin®: Dosage Regimen
Table 5.34 Photodynamic Therapy and Verteporfin® (Visudyne): Clinical DevelopmentalStatus
Table 5.35 Photodynamic Therapy and Verteporfin® (Visudyne): Clinical Trial Endpoints
Table 5.36 Photodynamic Therapy and Verteporfin® (Visudyne): Dosage Regimen
Table 5.37 Photodynamic Therapy and Verteporfin® (Visudyne): Key Insights
Table 5.38 Photodynamic Therapy and TOOKAD® VTP: Clinical Developmental Status
Table 5.39 Photodynamic Therapy and TOOKAD® VTP: Clinical Trial Endpoints
Table 5.40 Photodynamic Therapy and TOOKAD® VTP: Dosage Regimen
Table 5.41 Photodynamic Therapy and TOOKAD® VTP: Key Insights
Table 6.1 Light Activated Therapies: List of Clinical Trials
Table 7.1 Light Activated Therapies: List of Patents
Table 9.1 ADVANZ PHARMA: Product Portfolio
Table 9.2 Biofrontera: Product Portfolio
Table 9.3 Biofrontera: Recent Developments and Future Outlook
Table 9.4 biolitec Pharma: Product Portfolio
Table 9.5 Luzitin: Product Portfolio
Table 9.6 Luzitin: Recent Developments and Future Outlook
Table 9.7 Nanospectra Biosciences: Product Portfolio
Table 9.8 Nanospectra Biosciences: Recent Developments and Future Outlook
Table 9.9 photoatomic: Product Portfolio 
Table 9.10 photoatomic: Recent Developments and Future Outlook
Table 9.11 Rakuten Medical: Product Portfolio
Table 9.12 Rakuten Medical: Recent Developments and Future Outlook
Table 9.13 Theralase: Product Portfolio
Table 9.14 Theralase: Recent Developments and Future Outlook
Table 9.15 Steba biotech: Product Portfolio
Table 9.16 Steba biotech: Recent Developments and Future Outlook
Table 11.1 Light Activated Therapies: Distribution by Current Status of Development
Table 11.2 Light Activated Therapies: Distribution by Type of Light Activated Therapy
Table 11.3 Light Activated Therapies: Distribution by Therapeutic Area
Table 11.4 Light Activated Therapies: Distribution by Current Status of Development andTherapeutic Area
Table 11.5 Light Activated Therapies: Distribution by Photosensitive Dye
Table 11.6 Light Activated Therapies: Distribution by Type of Light
Table 11.7 Light Activated Therapies: Distribution by Target Patient Segment
Table 11.8 Light Activated Therapies: Distribution by Type of Therapy
Table 11.9 Light Activated Therapies: Distribution by Type of Developer
Table 11.10 Light Activated Therapies: Distribution by Popular Target Indication
Table 11.11 Leading Industry Players: Distribution by Number of Light Activated Therapies
Table 11.12 Leading Non-Industry Players: Distribution by Number of Light Activated Therapies
Table 11.13 Light Activated Therapy Developers: Distribution by Year of Establishment
Table 11.14 Light Activated Therapy Developers: Distribution by Company Size
Table 11.15 Light Activated Therapy Developers: Distribution by Location of Headquarters
Table 11.16 Light Activated Therapy Developers: Regional Landscape
Table 11.17 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 11.18 Clinical Trial Analysis: Distribution by Study Design and Trial Phase
Table 11.29 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model
Table 11.30 Clinical Trial Analysis: Distribution by Year and Trial Recruitment Status
Table 11.31 Clinical Trial Analysis: Distribution by Type of Sponsor(s)
Table 11.32 Leading Industry Players: Distribution by Number of Trials Registered
Table 11.33 Leading Non-Industry Players: Distribution by Number of Trials Registered
Table 11.34 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 11.34 Clinical Trial Analysis: Distribution by Purpose of Study
Table 11.35 Clinical Trial Analysis: Distribution by Emerging Focus Areas
Table 11.36 Clinical Trial Analysis: Distribution by Location of Trial(s)
Table 11.37 Clinical Trial Analysis: Distribution by Trial Status and Geography
Table 11.38 Patent Analysis: Distribution by Publication Year
Table 11.39 Patent Analysis: Distribution by Type of Patent
Table 11.40 Patent Analysis: Distribution by Patent Age
Table 11.41 Patent Analysis: Distribution by Geographical Location
Table 11.42 Patent Analysis: Distribution by Emerging Focus Areas
Table 11.43 Leading Patent Assignees: Distribution by Number of Patents
Table 11.44 Leading Industry Players: Distribution by Number of Patents
Table 11.45 Leading Non-Industry Players: Distribution by Number of Patents
Table 11.46 Patent Analysis: Distribution by CPC Symbols
Table 11.47 Light Activated Therapies: Patent Benchmarking
Table 11.48 Light Activated Therapies: Patent Valuation
Table 11.49 Light Activated Therapies Market, 2021-2030 (USD Million)
Table 11.50 Light Activated Therapies Market, 2021-2030: Distribution by Target Indication (USD Million)
Table 11.51 Light Activated Therapies Market, 2021-2030: Distribution by Key Players (USD Million)
Table 11.52 Light Activated Therapies Market, 2021-2030: Distribution by Geography (USD Million)
Table 11.53 Cetuximab Sarotalocan® (Rakuten Medical): Sales Forecast, 2021-2030 (USD Million)
Table 11.54 Photodynamic Therapy and Alacare® (medec): Sales Forecast, 2021-2030(USD 
Table 11.55 Photodynamic Therapy and Ameluz® (Biofrontera): Sales Forecast, 2021-2030(USD Million)
Table 11.56 Photodynamic Therapy and Aminolevulinic Acid (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030 (USD Million)
Table 11.57 Photodynamic Therapy and Foscan® (Temoporfin) (biolitec Pharma): SalesForecast, 2021-2030 (USD Million)
Table 11.58 Photodynamic Therapy and FuMeiDa® (Hemoporfin) (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030 (USD Million)
Table 11.59 Photodynamic Therapy and Levulan Kerastick® (Sun Pharmaceuticals): SalesForecast, 2021-2030 (USD Million)
Table 11.60 Photodynamic Therapy and Metvixia® (Metvix) (Galderma): Sales Forecast,2021-2030 (USD Million)
Table 11.61 Photodynamic Therapy and Porfimer Sodium / Photofrin® (ADVANZPHARMA): Sales Forecast, 2021-2030 (USD Million)
Table 11.62 Photodynamic Therapy and Verteporfin® (Visudyne) (Novartis): SalesForecast, 2021-2030 (USD Million)
Table 11.63 Photodynamic Therapy and TLD-1433 (Theralase): Sales Forecast, 2021-2030(USD Million)
Table 11.64 Photodynamic Therapy and TOOKAD® VTP (Steba biotech): Sales Forecast, World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1.     Ac BioScience 
  2.     Academic Medical Center (Academisch Medisch Centrum)
  3.     Acclarent 
  4.     Accovion (acquired by Clinipace)
  5.     ADVANZ PHARMA
  6.     Association for Innovation and Biomedical Research on Light and Image (AIBILI)
  7.     AinA
  8.     Alcon 
  9.     Alexandria University
  10.     Alpheus Medical
  11.     Ambalal Sarabhai Enterprises
  12.     American Society for Gastrointestinal Endoscopy
  13.     Amgen
  14.     An Hui Angkefeng Optoelectronic Technology
  15.     Anhui University
  16.     Asan Medical Center
  17.     Ascend Biopharmaceuticals
  18.     Association of Paediatric and Preventive Dentists of Serbia
  19.     Association to Prevent Blindness in Mexico
  20.     AstraZeneca
  21.     Autonomous University of Madrid
  22.     Axcan Pharma
  23.     Azienda Ospedaliero Universitaria Pisana (AOUP)
  24.     Barnes Retina Institute
  25.     Barretos Cancer Hospital
  26.     Bascom Palmer Eye Institute
  27.     Bausch + Lomb
  28.     Bausch Health
  29.     Bay Area Retina Associates
  30.     Bayer
  31.     Beckman Laser Institute & Medical Clinic
  32.     BeiJing Fullcan Biotechnology
  33.     Beijing Institute of Technology
  34.     Beijing University of Chemical Technology
  35.     Biodynamic Association (BDA)
  36.     Biofrontera
  37.     biolitec Pharma
  38.     BioVentures
  39.     Bispebjerg Hospital
  40.     Boehringer Ingelheim
  41.     Brigham and Women's Hospital
  42.     Bristol-Myers Squibb
  43.     Cairo University
  44.     California Retina Consultants
  45.     Canadian Cancer Trials Group (CCTG)
  46.     Carol Davila University of Medicine and Pharmacy
  47.     Case Comprehensive Cancer Center
  48.     Case Western Reserve University
  49.     Celgene
  50.     Cellvizio 
  51.     Central Norway Regional Health Authority
  52.     Central South University
  53.     CeramOptec
  54.     CEU Cardenal Herrera University
  55.     Changchun Institute of Applied Chemistry
  56.     Chimie ParisTech - PSL
  57.     China Medical University
  58.     China Pharmaceutical University
  59.     Chinese Academy of Medical Sciences
  60.     Chinese Academy of Tropical Agricultural Sciences
  61.     Chinese PLA General Hospital 
  62.     Chinese University of Hong Kong
  63.     Chongqing Medical University
  64.     Chonnam National University Hospital
  65.     Chu De Lille
  66.     Chulalongkorn University
  67.     Clinica Universidad de Navarra
  68.     Clinuvel Pharmaceuticals 
  69.     CMS Dental  
  70.     Complutense University of Madrid
  71.     Concordia Laboratories 
  72.     Coralluma 
  73.     CorePharma 
  74.     Cornell University
  75.     CosmoPHOS-nano
  76.     CranioVation
  77.     DR Nano
  78.     Dalian University of Technology
  79.     Dartmouth College
  80.     Dartmouth-Hitchcock Medical Center
  81.     De Haar Research Foundation (DHRF)
  82.     Dermatology, Laser & Vein Specialists of the Carolinas
  83.     Dermira
  84.     Dong-A University
  85.     Duke University
  86.     DUSA Pharmaceuticals
  87.     Eastern Cooperative Oncology Group (ECOG)
  88.     Eastern Liaoning University
  89.     Eastern Virginia Medical School
  90.     Eastern Virginia Medical School Foundation (EVMS)
  91.     Ecatepec Medical Center
  92.     Eisai 
  93.     Eli Lilly and Company
  94.     Emory University
  95.     Erasmus University Medical Center
  96.     European Commission
  97.     European Vision Clinical Research (EVICR)
  98.     Faculdade de Medicina do ABC
  99.     Fluminense Federal University (UFF)
  100. First Affiliated Hospital of Kunming Medical University
  101. First Moscow State Medical University
  102. Foundation Medicine
  103. Fourth Military Medical University
  104. Fraunhofer Society
  105. Fudan University
  106. Fujian Longhua Pharmaceutical
  107. Fujian Medical University
  108. Fujifilm
  109. Fuzhou University
  110. Galderma
  111. Genentech
  112. General Hospital of Ningxia Medical University
  113. George Washington University
  114. German Cancer Aid
  115. German Cancer Research Center
  116. GlaxoSmithKline
  117. Guangzhou Medical University
  118. Guilin University of Electronic Technology
  119. Guiyang College of Traditional Chinese Medicine
  120. Gwangju Institute of Science and Technology
  121. Hadassah Medical Center
  122. Hallym University Medical Center
  123. Harbin Institute of Technology
  124. Hasselt University
  125. Haukeland University Hospital 
  126. Henan Provincial People’s Hospital 
  127. Henan University of Science and Technology 
  128. Hepatopancreatobiliary Surgery Institute of Gansu Province
  129. Hisun Pharmaceutical 
  130. Hong Kong Baptist University
  131. Hong Kong University of Science and Technology
  132. Hospital Erasme
  133. Hospital of Southern Norway 
  134. Hospital of the Johann Wolfgang Goethe University
  135. Hospital Pérola Byington
  136. Huadong Hospital Affiliated to Fudan University
  137. HUS Helsinki University Hospital
  138. Illinois Retina Associates
  139. Indiana University
  140. Innovaderm Research
  141. Inova
  142. Institut National de la Sante et de la Recherche Medicale (Inserm)
  143. Institute of Chemistry Chinese Academy of Sciences
  144. Institute of Clinical and Experimental Medicine
  145. Ipsen
  146. IQVIA
  147. Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS)
  148. Janssen
  149. Jawaharlal Nehru Medical College
  150. Jessa Hospital
  151. Jewish General Hospital
  152. Jiangnan University
  153. Jilin Institute of Chemical Technology
  154. Johns Hopkins University
  155. Kafrelsheikh University
  156. Kiadis Pharma
  157. Kim's Eye Hospital
  158. King Chulalongkorn Memorial Hospital
  159. King Fahd University of Petroleum and Minerals
  160. King Saud University
  161. KLE Society’s Institute of Dental Sciences
  162. Korea Institute of Science and Technology (KIST)
  163. Korea Photonics Technology Institute
  164. Kumamoto University
  165. Kyung Hee University
  166. Laser & Skin Surgery Center of New York
  167. Lawson Health Research Institute
  168. Leiden University Medical Center
  169. LEO Pharma
  170. LifePhotonic 
  171. Light Sciences Oncology
  172. Lithuanian University of Health Sciences
  173. Liuzhou Workers Hospital
  174. Loma Linda University
  175. Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  176. Luzitin 
  177. MD Anderson Cancer Center
  178. Maisonneuve-Rosemont Hospital
  179. Marmara University
  180. Massachusetts General Hospital
  181. Mauna Kea Technologies
  182. Mayo Clinic
  183. McGill University Health Centre 
  184. medac
  185. Medelis
  186. Medical College of Wisconsin
  187. Medical University of Vienna
  188. Mediland Enterprise
  189. Medpace
  190. Memorial Sloan Kettering Cancer Center
  191. Merck
  192. Michigan State University 
  193. Mid Atlantic Retina 
  194. Miravant Pharmaceuticals
  195. Mundipharma Research
  196. Munster University Hospital (UKM)
  197. Nagoya City University
  198. Nanfang Hospital
  199. Nanjing Jiangning Hospital
  200. Nanjing University of Posts and Telecommunications
  201. Nanospectra Biosciences
  202. National Cancer Institute
  203. National Center for Research Resources 
  204. National Center for Tumor Diseases (NCT)
  205. National Chung Hsing University
  206. National Eye Institute
  207. National Institutes of Health (NIH)
  208. National Taiwan University
  209. National University Hospital
  210. National University of Singapore
  211. NeoMedLight
  212. New England Retina Associates
  213. Nihon University Hospital
  214. Nordland Hospital Trust
  215. Norris Cotton Cancer Center
  216. North Carolina State University
  217. North Florida Foundation for Research and Education
  218. Northwestern Polytechnical University
  219. Northwestern University
  220. Norwegian University of Science and Technology
  221. Nova Scotia Health Authority
  222. Novartis
  223. NYU College of Dentistry
  224. Oklahoma State University Center for Health Sciences
  225. On Target Laboratories
  226. Ondine Biomedical
  227. Ondine Biopharma
  228. Oregon Health and Science University
  229. Osaka University
  230. OSHU Knight Cancer Institute
  231. Oslo University Hospital
  232. Ostfold Hospital Trust
  233. Otsuka Electronics
  234. Pacific Derm
  235. Paderborn University
  236. Peking University
  237. Peking University People's Hospital
  238. Peking University School of Stomatology
  239. Pfizer
  240. Pharma Power Biotec 
  241. Photocure
  242. photonamic
  243. Pinnacle Biologics
  244. Poitiers University Hospital
  245. Pontifical Catholic University
  246. PrimeVigilance
  247. Privolzhsky Research Medical University
  248. PSL Research University
  249. Purdue Research Foundation
  250. Qingdao University
  251. QLT 
  252. Radboud University
  253. Rakuten Medical
  254. Rapid Labs
  255. Regeneron Pharmaceuticals
  256. Renji Hospital
  257. Republic Polytechnic
  258. Retinal Consultants Medical 
  259. Rhode Island Hospital
  260. RMW Cho Group 
  261. Roche
  262. Rogers Sciences
  263. Rosalind Franklin University of Medicine and Science
  264. Roswell Park Cancer Institute
  265. Rothman Orthopaedic Institute
  266. Ruhr University-Bochum 
  267. RWTH Aachen University
  268. Salt & Light Pharmaceuticals
  269. Samsung Medical Center
  270. São Paulo Research Foundation (FAPESP)
  271. SBI Pharmaceuticals
  272. Seoul National University Bundang Hospital
  273. Seoul St. Mary's Hospital
  274. Shahid Beheshti University of Medical Sciences
  275. Shanghai Dermatology Hospital
  276. Shanghai First People's Hospital North Branch
  277. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical 
  278. Shanghai General Hospital
  279. Shanghai Jiao Tong University School of Medicine
  280. Sharp
  281. Sheffield Teaching Hospitals NHS Foundation Trust
  282. Shenzhen Hanguang Technology
  283. Shenzhen Institute of Advanced Technology
  284. Shenzhen Institute of Information Technology
  285. Shenzhen International Institute for Biomedical Research
  286. Shimadzu
  287. Shin Kong Wu Ho-Su Memorial Hospital
  288. Sichuan Provincial People's Hospital
  289. Sidney Kimmel Comprehensive Cancer Center
  290. Singapore National Eye Centre
  291. South China University of Technology
  292. Southeast University
  293. Southern Illinois University
  294. Southern University of Science and Technology
  295. Spanish National Research Council
  296. SpectraCure
  297. St. Jude Children's Research Hospital
  298. St. Olav's University Hospital
  299. St. Vincent's Private Hospital
  300. Stand Up To Cancer
  301. Stanford University
  302. Steba biotech 
  303. Sun Pharma
  304. Sun Yat-sen University
  305. Sunnybrook Health Sciences Centre
  306. Suzhou Hvha Medical Technology
  307. SVS Institute of Dental Sciences
  308. Swiss National Science Foundation (SNSF)
  309. Tampere University
  310. Tan Tock Seng Hospital
  311. Taoyuan General Hospital, Ministry of HealthTeikyo University
  312. The Affiliated Hospital of Xuzhou Medical University
  313. Tel Aviv Sourasky Medical Center
  314. Texas Retina Associates
  315. The Catholic University of America
  316. The Cleveland Clinic
  317. The Colorado Health Foundation
  318. The First Affiliated Hospital of Xinjiang Medical University
  319. The First Affiliated Hospital with Nanjing Medical University
  320. The Lowy Medical Research Institute
  321. The Netherlands Cancer Institute
  322. The Regents of the University of Michigan
  323. The Second Affiliated Hospital of Xi'an Jiaotong University
  324. The Second Xiangya Hospital of Central South University
  325. The Third Xiangya Hospital of Central South University
  326. The University of Texas at Austin
  327. The First Affiliated Hospital of Xi'an Jiaotong University
  328. Theralase Technologies
  329. Tokyo Institute of Technology
  330. Tongji University
  331. Tripler Army Medical Center
  332. Tsinghua University
  333. Tufts Medical Center
  334. UCB Pharma
  335. UCSF Benioff Children Hospital 
  336. University College Cardiff Consultants
  337. University College Hospital
  338. University College London
  339. University Health Network
  340. University Hospital Heidelberg
  341. University Hospital of North Norway 
  342. University Hospital Regensburg
  343. University Hospitals Cleveland Medical Center
  344. University Institute of Applied Ophthalmobiology (IOBA)
  345. University of Alabama at Birmingham
  346. University of Arizona
  347. University of British Columbia
  348. University of California Irvine
  349. University of Coimbra
  350. University of Cologne
  351. University of Dundee
  352. University of Exeter
  353. University of Georgia
  354. University of Hamburg
  355. University of Kansas
  356. University of Kansas Medical Center
  357. University of Jyväskylä
  358. University of La Frontera
  359. University of Lille
  360. University of Lodz
  361. University of Manitoba
  362. University of Massachusetts
  363. University of Miami
  364. University of Michigan
  365. University of Münster
  366. University Of Mysore (UoM)
  367. University of Navarra
  368. Universidade Nove de Julho
  369. University of Oxford
  370. University of Padua
  371. University of Pennsylvania
  372. University of Regensburg
  373. University of Rochester
  374. University of Salzburg
  375. University of South Carolina
  376. University of South Florida
  377. University of Toronto
  378. University of Washington
  379. University of Wisconsin
  380. University of Zurich
  381. Ural Federal University
  382. Ural Institute of Cardiology
  383. USHEALTH Group 
  384. Vaasa Central Hospital
  385. Vestre Viken Hospital Trust
  386. VieCuri Medical Center
  387. Vienna Institute for Research In Ocular Surgery
  388. Wake Forest University Health Sciences
  389. WCCT Global
  390. Weill Medical College of Cornell University
  391. Weizmann Institute of Science
  392. Wenzhou Jingyu Medical Instruments 
  393. Wenzhou Medical College Affiliated Yanshiguang Hospital
  394. Wenzhou Medical University
  395. West China Hospital
  396. Wright State Physicians
  397. Wuhan Institute of Technology
  398. Xidian University
  399. Xinjiang Medical University
  400. Xuzhou Medical University
  401. Zhejiang Hisun Pharmaceutical
  402. Zhejiang University
  403. Zhejiang University of Science and Technology
  404. Zhongshan Hospital Xiamen University
  405. Zhuhai People's Hospital
  406. Zimmer BioTech
  407. Zimmer MedizinSysteme
  408. Zonguldak Bulent Ecevit University

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.